Literature DB >> 16730534

Intratympanic steroid treatment in idiopathic sudden sensorineural hearing loss: a control study.

John Xenellis1, Nikolaos Papadimitriou, Thomas Nikolopoulos, Paulos Maragoudakis, John Segas, Antonios Tzagaroulakis, Eleutherios Ferekidis.   

Abstract

BACKGROUND AND
OBJECTIVE: Although systemic steroids in sudden sensorineural hearing loss (SSHL) appears to be the most effective and the most widely accepted treatment today, a significant number of patients do not respond to steroid treatment or they cannot receive steroids for medical reasons. Intratympanic (IT) administration of steroids appears to be an alternative or additional method of management without the side effects of intravenous steroids. The aim of this study is to investigate the effectiveness and safeness of IT administration of steroids in patients who had not responded to IV treatment and to compare treatment efficacy with controls. STUDY DESIGN AND
SETTING: Our study consisted of 37 patients with SSHL who, at the end of 10 days of therapy with intravenous steroids as a 1st line treatment, had pure-tone 4-frequency (0.5, 1, 2, and 4 kHz) average (PTA) of worse than 30 dB or worse than 10 dB from the contralateral ear (defined as failed intravenous treatment). They were randomized into 2 groups, treatment and control. The 19 patients of the treatment group received approximately 0.5 mL sterile aqueous suspension of methylprednisolone acetate in a concentration of 80 mg/2 mL by direct injection. The procedure was carried out 4 times within a 15-day period. An audiogram was performed before each injection and approximately 1.5 months after the last session.
RESULTS: All patients tolerated the procedure well. No perforation or infection was noticed in any of the patients at their last visit. With regard to the 19 patients who received intratympanic treatment, in 9 patients, the PTA threshold improved more than 10 db, in 10 patients there was no change greater than 10 db, and no patients deteriorated more than 10 db. In the control group, none of the patients showed any change greater than 10 db. The difference was statistically significant (P = 0.002). The treatment group showed an improvement in mean PTA of 14.9 dB, whereas the control group showed a deterioration of 0.8 dB, and this difference also was statistically significant (P = 0.0005). IT treatment (P = 0.0001), better post-IV PTA (P = 0.0008), and absence of vertigo (P = 0.02) were good predictors of the outcome. In contrast, sex, age, affected ear, days to admission, and pattern of the initial audiogram showed no significant influence on the outcome. CONCLUSION AND SIGNIFICANCE: IT steroid administration after failed intravenous steroids is a safe and effective treatment in sudden sensorineural hearing loss.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16730534     DOI: 10.1016/j.otohns.2005.03.081

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  38 in total

1.  Early combination treatment with intratympanic steroid injection in severe to profound sudden sensorineural hearing loss improves speech discrimination performance.

Authors:  Young Ho Kim; Kyung Tae Park; Byung Yoon Choi; Min Hyun Park; Jun Ho Lee; Seung-Ha Oh; Sun O Chang
Journal:  Eur Arch Otorhinolaryngol       Date:  2011-12-08       Impact factor: 2.503

2.  [Intratympanic glucocorticoid therapy of sudden hearing loss].

Authors:  S K Plontke
Journal:  HNO       Date:  2010-10       Impact factor: 1.284

Review 3.  Issues, indications, and controversies regarding intratympanic steroid perfusion.

Authors:  Mohamed Hamid; Dennis Trune
Journal:  Curr Opin Otolaryngol Head Neck Surg       Date:  2008-10       Impact factor: 2.064

4.  Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments.

Authors:  Gülce Ermutlu; Nilda Süslü; Taner Yılmaz; Sarp Saraç
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-07-29       Impact factor: 2.503

5.  Transtympanic administration of short interfering (si)RNA for the NOX3 isoform of NADPH oxidase protects against cisplatin-induced hearing loss in the rat.

Authors:  Debashree Mukherjea; Sarvesh Jajoo; Tejbeer Kaur; Kelly E Sheehan; Vickram Ramkumar; Leonard P Rybak
Journal:  Antioxid Redox Signal       Date:  2010-09-01       Impact factor: 8.401

Review 6.  Intratympanic steroids as primary initial treatment of idiopathic sudden sensorineural hearing loss. The Hospital Universitario Ramón y Cajal experience and review of the literature.

Authors:  Tomás Labatut; María José Daza; Antonio Alonso
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-12-20       Impact factor: 2.503

7.  Dexamethasone concentration gradients along scala tympani after application to the round window membrane.

Authors:  Stefan K Plontke; Thorsten Biegner; Bernd Kammerer; Ursular Delabar; Alec N Salt
Journal:  Otol Neurotol       Date:  2008-04       Impact factor: 2.311

8.  Use of intratympanic dexamethasone for the therapy of low frequency hearing loss.

Authors:  Necat Alatas
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-12-20       Impact factor: 2.503

9.  Effectiveness of intratympanic dexamethasone for refractory sudden sensorineural hearing loss.

Authors:  Omer Erdur; Fatma Tulin Kayhan; Ahmet Adnan Cirik
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-06-16       Impact factor: 2.503

10.  Modified intratympanic treatment for idiopathic sudden sensorineural hearing loss.

Authors:  Emrah Kara; Fikret Cetik; Ozgür Tarkan; Ozgür Sürmelioğlu
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-10-28       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.